Yep, our float is low and our market cap is low as well. You can bet that 6 months before a data readout, TPIV will be on the radar of the bio traders. If there is going to be a 6 month readout next year, then expect the chatter to begin about 6 months before it occurs---- that is why it is wise to accumulate shares NOW, because by this year end, the chatter will begin, and that will be here very soon.
It could be very possible to get a market cap run towards $300M in anticipation of a data readout. If you get a good data read out, a $300M market cap will be the base. Doing the math, that is close to 10 times current cap and price per share. They may up list then, or maybe that happens sooner. If they up list sooner, you can bet that a market maker will be on board to move the shares around and create hoop-la for an up list and volume.
The other compelling thing here is that they will have multiple P2 trials up and running with data readout catalysts within the same year possibly, so $300M market cap could be small given that there is a pipeline of other candidates with value adding of possibly $300M EACH, so the value could go towards $1 billion quite quickly. Of course, if this data is good, I don't expect TPIV to exist very long - it will be gobbled up since immunotherapy is 'up and coming' in cancer treatment and TPIV seems to have the "right stuff."
News 
Market Data 
Discover 
